FindTrial
Sign In

A comparison of efficacy and safety of Antihypertensive drugs used in combination and adherence to medication in patients of Hypertension

A comparative evaluation of the efficacy and safety profile of Antihypertensive drugs used in rational combination and adherence to medication in patients of Hypertension in a Tertiary Care Centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/09/057435
Enrollment
354
Registered
2023-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr. Madhumita Dixit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed patients 2. Patients of either sex 3. Age = 18 4. Patients with confirmed diagnosis of Hypertension based on clinical presentation and JNC 8 criteria 5. Patients with no other comorbidities

Exclusion criteria

Exclusion criteria: 1. Age 2. Patients with other comorbidities 3. Previously diagnosed hypertensive patients 4. Secondary Hypertension 5. Patient not giving consent

Design outcomes

Primary

MeasureTime frame
1)Comparative analysis of efficacy of combination of Hydrochlorothiazide + Amlodipine vs Hydrochlorothiazide + Telmisartan vs Hydrochlorothiazide + Ramipril 2)Comparative analysis of safety of combination of (Hydrochlorothiazide + Amlodipine vs Hydrochlorothiazide + Telmisartan vs Hydrochlorothiazide + Ramipril) 3)Comparison of Adherence of patients to combination of Hydrochlorothiazide + Amlodipine vs Hydrochlorothiazide + Telmisartan vs Hydrochlorothiazide + Ramipril 4)Comparative analysis of Pharmacoeconomic considerations of Hydrochlorothiazide + Amlodipine vs Hydrochlorothiazide + Telmisartan vs Hydrochlorothiazide + Ramipril Timepoint: 1 month—

Secondary

MeasureTime frame
Diabetes ,dyslipidemia, ADR monitoringTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr Rakesh Chandra Chaurasia

Moti Lal Nehru Medical College

dixitmadhumita17@gmail.com9415615064

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026